Page 101 - CUA KIDNEY CANCER HANDBOOK 2020

References

Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs. deferred
cytoreductive nephrectomy in patients with synchronous metastatic renal cell
carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol.
2019;5:164-170.

Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib vs. sunitinib as initial targeted
therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk:
The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591-7.
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib vs. everolimus in advanced
renal cell carcinoma (METEOR): Final results from a randomized, open-label, phase 3
trial. Lancet Oncol. 2016;17:917-27.
Dudani S, Graham J, Wells JC, et al. First-line Immuno-Oncology Combination
Therapies in Metastatic Renal-cell Carcinoma: Results from the International
Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019
Dec;76(6):861-867.

Dudani S and Heng DYC. Selecting patients with metastatic renal cell carcinoma for
cytoreductive nephrectomy. December 18, 2019. https://dailynews.ascopubs.org/
do/10.1200/ADN.19.190484/full/.
Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact
of sunitinib on overall survival in the treatment of patients with metastatic renal cell
cancer. Cancer. 2009;115:776-83.
Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients
with metastatic renal cell carcinoma treated with vascular endothelial growth factor-
targeted agents: Results from a large, multicenter study. J Clin Oncol. 2009;27:
5794-5799.
Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other
models of the International Metastatic Renal-Cell Carcinoma Database Consortium
prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141-148.
Mason RJ, Wood L, Kapoor N, et al. Kidney Cancer Research Network of Canada
(KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients
with metastatic renal cell carcinoma. Can Urol Assoc J. 2019;13:166-174.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab vs. everolimus in advanced
renal-cell carcinoma. N Engl J Med. 2015;373:1803-13. [CheckMate 025]
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell
carcinoma: A double-blind, randomized, placebo-controlled, phase 3 trial. Lancet.
2008;372:449-56. [RECORD-1]
Motzer RJ, Haas NB, Donskov F, et al. Randomized phase 3 trial of adjuvant
pazopanib vs. placebo after nephrectomy in patients with localized or locally
advanced renal cell carcinoma. J Clin Oncol. 2017;35:3916-23.
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib vs. sunitinib in metastatic renal-cell
carcinoma. N Engl J Med. 2013;369:722-31. [COMPARZ]

Continued on next page

Practical Approaches to Managing Advanced Kidney Cancer 83